8-K: OS Therapies Secures $6 Million in Private Placement to Advance Cancer Immunotherapy

OS Therapies has successfully priced a $6 million private placement to fund the clinical and regulatory milestones for its lead therapeutic candidate, OST-HER2.

Summary

• OS Therapies has entered into agreements for a private placement of 1.5 million units at $4.00 per unit, expected to generate $6 million in gross proceeds.
• Each unit includes one share of Series A Senior Convertible Preferred Stock, initially convertible into one share of common stock, and one warrant to purchase one share of common stock.
• The conversion price of the preferred stock is $4.00, and the warrant exercise price is $4.40 per share.
• The private placement is expected to close around December 27, 2024, pending customary closing conditions.
• The company plans to use the funds for working capital, focusing on clinical and regulatory milestones for OST-HER2, and for general corporate purposes.
• OST-HER2 has received rare pediatric disease, fast track, and orphan drug designations from the FDA.
• Brookline Capital Markets acted as the placement agent, with Ceros Financial Services as a selected dealer.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting a successful capital raise and progress in clinical development. However, it also acknowledges the risks associated with the private placement and the company's future success.

Positives

• The private placement provides OS Therapies with a cash runway into 2026.
• The company has secured funding from pre-IPO and IPO investors, indicating strong investor confidence.
• The company is focused on advancing OST-HER2, which has received multiple FDA designations.
• The company has a next generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC).

Risks

• The private placement is subject to customary closing conditions, which may not be satisfied.
• The company's future success depends on the clinical and regulatory milestones for OST-HER2.
• The company's financial performance is subject to market conditions and other risks.

Future Outlook

The company intends to use the proceeds from the private placement for working capital, primarily focused on the clinical and regulatory milestones to support commercialization of the Companys lead therapeutic candidate OST-HER2 in the treatment of recurrent, resected metastatic osteosarcoma in the United States in 2025, and for general corporate purposes.

Management Comments

• The company intends to use the proceeds from the private placement for working capital, primarily focused on the clinical and regulatory milestones to support commercialization of the Companys lead therapeutic candidate OST-HER2 in the treatment of recurrent, resected metastatic osteosarcoma in the United States in 2025, and for general corporate purposes.

Industry Context

This announcement reflects a trend in the biotechnology industry where companies raise capital through private placements to fund clinical trials and regulatory milestones. The focus on cancer immunotherapy and antibody drug conjugates aligns with current trends in oncology research and development.

Comparison to Industry Standards

• The private placement structure, involving preferred stock and warrants, is a common method for biotech companies to raise capital.
• The use of proceeds for clinical and regulatory milestones is typical for companies in this stage of development.
• The company's focus on OST-HER2, which has received multiple FDA designations, is a positive sign for its potential.
• The company's next generation Antibody Drug Conjugate (ADC) platform, known as tunable ADC (tADC), is a novel approach that could provide a competitive advantage.

Stakeholder Impact

• Shareholders: The private placement may result in dilution of existing shares, but it also provides funding for future growth.
• Employees: The funding provides job security and resources for further development.
• Customers: The funding supports the development of new treatments for cancer.
• Suppliers: The funding may lead to increased demand for supplies and services.
• Creditors: The funding improves the company's financial stability.

Next Steps

• The private placement is expected to close on or about December 27, 2024.
• The company will use the proceeds for working capital and clinical development.
• Data from the OST-HER2 Phase 2b trial will be announced during the week of the JP Morgan Healthcare Conference in January 2025.

Key Dates

Keywords

private placement, cancer immunotherapy, antibody drug conjugate, OST-HER2, osteosarcoma, biotechnology, clinical trial, FDA, Series A Senior Convertible Preferred Stock, warrants